×ðÁú¿­Ê±

EN
EN
  • ÓªÒµ×Éѯ

    Öйú£º

    Email: marketing@medicilon.com.cn

    ÓªÒµ×ÉѯרÏߣº400-780-8018

    £¨½öÏÞЧÀÍ×Éѯ £¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©

    ´¨É³×ܲ¿µç»°: +86 (21) 5859-1500

    ÍâÑó£º

    +1(781)535-1428(U.S.)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com

ÔÚÏßÁôÑÔ¡Á
µã»÷Çл»
News information
ÐÂÎÅ×ÊѶ

ѰÕÒÐÂÒ©Ò»Ö±ÔÚ·ÉϰеãÑо¿²»¿ÉµôÒÔÇáÐÄ

2017-06-07
|
»á¼ûÁ¿£º
°ÐµãµÄ·¢Ã÷ºÍÈ·ÈÏ £¬¹ØÓÚҩѧÊÂÇéÕß¶øÑÔ £¬ÊÇÒ»Ïî¼ÈÖ÷ÒªÓÖÄÑÌâµÄʹÃü £¬Í¨³£ £¬Ò©Îï×÷ÓõÄаеãÒ»µ©±»·¢Ã÷ £¬ÍùÍù»á³ÉΪһϵÁÐÐÂÒ©·¢Ã÷µÄÍ»ÆÆ¿Ú¡£ÓÚÊÇ £¬ÔÚѰÕÒеÄÒ©Îï°ÐµãÉÏ £¬¸÷¹ú¿ÆÑÐְԱȫÁ¦ÒÔ¸° £¬¸÷´óÒ©Æó·×·×ͶÈëÖØ½ð¾ÙÐÐÖÖÖÖÊÔÑé £¬ÒÔÆÚÄܹ»Í¨¹ýÕÒµ½Ò»¸öеÄÒ©Îï°Ðµã¶øÑз¢³öÓâÔ½µÐÊÖµÄÐÂÒ©¾ºÆ·¡£È»¶ø £¬Ê§°ÜµÄ½Ìѵ¸æËßÎÒÃÇ £¬²¢·Çÿһ¸ö¹¦Ð§Ð͵ÄÉúÎï´ó·Ö×Ó £¬¶¼¿ÉÒÔµ±×öÒ©Îï°ÐµãÈ¥¾ÙÐпª·¢ £¬ÉúÎï´ó·Ö×ÓÖ»ÓоßÓÐÒ»¶¨µÄÌØµã £¬²Å¿ÉÒÔ±»ÎÒÃÇËø¶¨¼Ì¶ø¿ª·¢³É°Ð¡£ÒÔÊÇ £¬Ò©Îï°ÐµãµÄѧϰ¡¢Ã÷È·ºÍ¸ÐÎò £¬¹ØÓÚÿ¸öÐÂÒ©Ñз¢Ö°Ô± £¬¾ÍÏԵøñÍâÖ÷Òª¡£

1. ʲôÊÇ¡°Ò©Îï°Ðµã¡±£¿Ó¦¾ß±¸ÔõÑùµÄ»ù±¾Ìõ¼þ£¿

ÔçÔÚ1891Äê £¬PaulEhrlich(¿¹ÉúËØ·½ÃæÐ¢Ë³Í»³ö)ÆäʱÕýÔÚʵÑéÓÃȾÁÏȾɫϸ¾úϸ°û £¬Ê±´úÌá³ö £¬¡°Ï¸°û¿ÉÄÜÊÇÒ»¸ö¡®´ó·Ö×Ó¡¯ £¬ÕâÖÖ¡®Ï¸°û-·Ö×Ó¡¯±£´æ¡®²àÁ´¡¯À´ÎüÊÕÍⲿµÄÓªÑø¡± £¬²¢½«ÆäÃüÃûΪ¡°²àÁ´ÊÜÌ塱¡£Paul EhrlichÏàÐÅ £¬Ï¸¾ú±£´æÊÜÌå²¢¿ÉÓëȾÁÏ·Ö×Ó±¬·¢»¯Ñ§·´Ó¦ £¬ËæºóÔÚ½ÓÏÂÀ´µÄÊÔÑéÖÐ £¬ÓÖÏà¼ÌÌá³öÁË¡°»¯ÁÆ¡±ÒÔ¼°¡°Ò©ÎïÊÇͨ¹ý×÷ÓÃÓڰеã·Ö×Ó¶ø±¬·¢×÷Óᱵȿ´·¨ºÍ¼Ù˵¡£ÏÖÔÚ £¬ÕâÒ»¿´·¨ÈÔÈ»±£´æ £¬Å£½òÉúÎﻯѧ´ÇÊ齫¡°Ò©Îï°Ðµã¡±½ç˵Ϊ¡°ÓëÌØÊ⻯ºÏÎïÏ໥×÷Óò¢±»µ÷ÀíµÄÉúÎïʵÌå £¬Í¨³£ÎªÂѰ׻ò»ùÒò¡±¡£ÔÚÄÇÖ®ºó £¬Ò»ÏµÁÐÓëÖ®Ïà¹ØµÄѧ˵Ïà¼Ì±¬·¢ £¬ÆäÖб£´æÒ»¶¨Îóµ¼ÐԵļ´ÊÇ¡°Ò»¸öÒ©Îï¶ÔÓ¦Ò»¸ö°Ðµã £¬ÇÒÕâ¸ö°ÐµãÊÇÌØÊâÇÒΨһµÄ¡±¡­¡­Ëæ×Å¿ÆÑ§µÄһֱǰ½ø £¬ÓÈÆäÊÇÒ©ÀíѧµÄÒ»Ö±Éú³¤ £¬´ó²¿·Ö¼Ù˵²»¹¥×ÔÆÆ¡£
Ëæ×Å¿ÆÑ§µÄÒ»Ö±Éú³¤ £¬ÏÖÔÚÒ©Îï°Ðµã»ù±¾¿É½ç˵Ϊ¡°Äܹ»ÓëÌØ¶¨Ò©ÎïÌØÒìÐÔÁ¬Ïµ²¢±¬·¢ÖÎÁƼ²²¡×÷Óûòµ÷ÀíÐÄÀí¹¦Ð§×÷ÓõÄÉúÎï´ó·Ö×Ó»òÉúÎï·Ö×ӽṹ¡±¡£ÓÉ´Ë¿ÉÖª £¬Ò©Îï°ÐµãÍùÍùÊÇÉúÎï´ó·Ö×Ó £¬²¢¾ßÓкÍÒ»Ð©ÌØÊ⻯ºÏÎïÄܹ»¡°Á¬ÏµµÄ²¿Î»¡± £¬µ±ÏìÓ¦»¯Ñ§ÎïÖÊÓëÖ®±¬·¢Á¬Ïµºó £¬½á¹¹»á±¬·¢Êʵ±µÄת±ä £¬ÇÒÕâ¸öת±ä×îºÃÊÇ¡°¿ÉÄæµÄ¡±¡£½á¹¹×ª±äºóµÄÕâ¸öÉúÎï´ó·Ö×Ó £¬»áʩչһ¶¨µÄÐÄÀí²¡Àí×÷Óà £¬¼´ÌåÏÖ³ö¡°Ò©Ð§¡± £¬ÇÒÔÚ»úÌåÖØ´óϵͳÖÐÕ¼ÓÐÖ÷µ¼×÷Ó᣶ø²¡ÀíÌõ¼þÏ £¬¸ÃÎïÖʵıí´ï¡¢»îÐÔ¡¢½á¹¹»òÌØÕ÷¿ÉÒÔ±¬·¢×ª±ä £¬ÕâÖÖת±ä¿ÉÒÔÊÇÔ­·¢ÐÔ £¬Ò²¿ÉÒÔÊǼ̷¢ÐԵġ£±ðµÄ £¬ÔÚÌåÄÚ¿ÉÄܱ£´æÄÚÔ´ÐÔÒ²¿ÉÄܱ£´æÍâÔ´ÐÔµÄÄÜÓë¸Ã·Ö×Ó»ò½á¹¹Á¬ÏµµÄÎïÖÊ £¬Õâ¸öÁ¬ÏµµÄÎïÖÊ¿ÉÒÔ×÷ΪҩÎïÓÃÓÚ·ÀÖμ²²¡¡£ÒÔÉÏ¿ÉÒÔ˵ £¬ÊÇÒ»¸öÉúÎï´ó·Ö×Ó×÷ΪҩÎï°Ðµã×îΪ»ù±¾µÄÌõ¼þ £¬ËäÈ» £¬Ò»¶¨Ìõ¼þ×ÔÈ»ÊDZ£´æÏìÓ¦µÄ¡¢ºÏÊʵÄÒ©Îï¡£

2. ½üÄêÀ´ £¬Ò©Îï°ÐµãµÄÉú³¤ÇéÐÎ

ÓÉÓÚÒ©Îï°ÐµãµÄÖ÷Òª¼ÛÖµºÍ×÷Óà £¬½üÄêÀ´ £¬Ëæ×Å·Ö×ÓÉúÎïѧ¡¢ÈËÀà»ùÒò×é¡¢ÂѰ×ÖÊ×éµÈÉúÃü¿ÆÑ§ºÍÊÖÒÕÒªÁìµÄÉú³¤ £¬ÈËÃǶÔÒ©Îï°ÐµãµÄÑо¿ÈÈÇé¿Õǰ¸ßÕÇ £¬Ò©Îï°ÐµãµÄ·¢Ã÷ºÍÈ·Ö¤¼º¾­³ÉΪÉúÃü¿ÆÑ§ÁìÓòÑо¿ÈÈÃÅ¡£ÇÒÆ¾Ö¤ÈËÀà»ùÒò×éÑо¿Ð§¹ûÕ¹ÍûµÄϸ°ûÄÚÒ©Îï·Ö×ÓÄÜ×÷Óõİеã £¬¾ÝÊØ¾ÉÔ¤¼Æ £¬Äܹ»³ÉΪҩÎï°ÐµãµÄÔ¼ÓÐ5000¡«10000¸ö £¬ÕâЩ°Ðµã×ã¹»¿ÆÑÐÖ°Ô±ÃÆÍ·Ñо¿Ò»¶Îʱ¼äÁË¡£
2016Äê £¬¡¶Nature Reviews Drug Discovery¡·µÄÁ½ÆªÎÄÕÂÆÊÎöÁË2016Äê°ÐµãµÄÑо¿ÇéÐÎ £¬ÆäÖÐһƪ¹²Éæ¼°661¸ö°Ðµã(ÈËÀàÂѰ×) £¬285¸öΪ¾­ÓÉÑéÖ¤µÄ°Ðµã £¬376¸öΪае㣻Áíһƪ¹²Éæ¼°893СÎÒ˽¼ÒÀàºÍ²¡Ô­ÌåÑÜÉúµÄÉúÎï·Ö×Ó(ͳ¼ÆFDAÅú×¼µÄ1578¸öÒ©Îï) £¬°üÀ¨667СÎÒ˽¼ÒÀà»ùÒò×éÑÜÉúÂѰ× £¬ÕâЩ°Ðµãµ±ÖÐ £¬GÂѰ׿ÁªÊÜÌå¡¢Àë×ÓͨµÀ¡¢¼¤Ã¸¡¢ºËÊÜÌåµÄÑо¿Ïà¶Ô½Ï¶à¡£
×ðÁú¿­Ê± - ÈËÉú¾ÍÊDz«!

3. °ÐµãÈ·Ö¤µÄ¼ÛÖµºÍÒâÒå

½ñÌì £¬Ì½Ë÷Ò©Îï°ÐµãµÄÒªÁìÒѾ­ÓÐÐí¶àÐí¶à £¬¶øÓÉÓڰеãÔÚÒ©Îï·¢Ã÷Àú³ÌÖеÄְλºÍ¼ÛÖµ £¬ÈËÃÇÖð½¥½«¹Ø×¢µã¾Û½¹ÔÚÁ˰еã¼òÖ±ÈÏÉÏ¡£¶ø°Ðµã¼òÖ±ÈÏ×ÔÈ»Àë²»¿ªÒ»Ð©ºÏÊʵķÖ×Ó £¬Í¨¹ý¡°»ùÓڰеãµÄɸѡսÂÔ¡±ºÍ¡°±íÐÍɸѡսÂÔ¡±¿ÉÒÔÏÈɸ³öһЩ¸ÐÐËȤµÄºòѡҩÎï £¬Ëæºó¶Ô°Ðµã¾ÙÐÐÈ·ÈÏ¡¢ÑéÖ¤ £¬Ê¹Ö®³ÉÎªÕæÕýÒâÒåÉϵġ°Ò©Îï°Ðµã¡±¡£
¹ØÓڰеãµÄÑéÖ¤Àú³Ì £¬¼òÒªÏÈÈÝÈçÏ£ºÊ×ÏÈ £¬È·ÈϰеãÔÚϸ°ûʵÑéÖÐÊÇ·ñ¾ßÓе÷Àí»¯ºÏÎïµÄÉúÎï»îÐÔ £¬Õâ¿Éͨ¹ýRNA×ÌÈÅÊÖÒÕĬȻijһ»ùÒò(СÊó) £¬ÊÓ²ìÊÇ·ñ¾ßÓÐÒ©Îï×÷ÓúóµÄÖ¢×´ £¬ÈôÒ©ÎïûÓÐÒýÆðЧӦ £¬ËµÃ÷Ò©ÎïÊÇͨ¹ýÕâÒ»ÌØ¶¨°Ðµã×÷ÓõÄ¡£Òò´Ë £¬ºòÑ¡°ÐµãµÄͬϵÎïÒ²Òª±»ÄÉÈë˼Á¿¹æÄ£ £¬×ÝÈ»ÆäÔÚ×î³õµÄɸѡÖв¢Ã»Óб»Ê¶±ð¡£±ðµÄ £¬Ò»¸öÎïÖÊ¿ÉÄܾßÓй¦Ð§ÐÔ»ñµÃµÄ»îÐÔ £¬°ÐµãµÄȱʧÒà»áÒÖÖÆ´ËÎïÖʵĻîÐÔ¡£³ýÁËRNA×ÌÈÅÊÖÒÕ £¬Ò²¿ÉÒÔÓÃcDNA¹ý±í´ïÀ´½¨ÉèÒ©Îï-°Ðµã×÷ÓùØÏµ £¬ÕâÖÖÒªÁìÀàËÆÓÚ½ÍĸÖеĿ½±´ÊýÒÖÖÆÕ÷Ïó £¬°ÐµãµÄ¹ý±í´ï¿ÉÄÜ»áÒÖÖÆÒ©ÎïµÄ»îÐÔ £¬ÕâÖÖÒªÁì¹ØÓÚÑé֤Ĥ°Ðµã¼«ÎªÖ÷Òª¡£Ò»µ©¼Ù¶¨µÄ°Ðµãͨ¹ý¹¦Ð§ÊµÑéµÄÑéÖ¤ £¬¾ÍÐèÒª¶ÔС·Ö×ÓÎïÖʼ°°ÐµãµÄÇ׺ÍÁ¦¾ÙÐÐÁ¿»¯¡£ÕâÒ»Àú³Ì¿ÉÒÔͨ¹ýÍâòµÈÀë×Ó¹²Õñ»òÕßµÈÎÂÁ¿ÈÈ·¨ÊÖÒÕÍê³É £¬ÈôÊǼٶ¨µÄ°ÐµãÊÇÒ»ÖÖø £¬ÔòҪͨ¹ýø¶¯Á¦Ñ§ÊµÑéȨºâ´ËÎïÖʵÄø»îÁ¦¡£×îºó £¬ÐèҪͨ¹ýNMR»ò¹²½á¾§ÊµÑé¾ÙÐиüΪÑÏ¿áµÄÑéÖ¤ £¬½ø¶ø»ñµÃÒ©Îï-°Ðµã¸´ºÏÎïµÄÈýά½á¹¹¡£ÕâЩÐÅÏ¢²»µ«¿ÉÒÔÑéÖ¤ÎïÀíÉϵĹØÁªÐÔ £¬Ò²¿ÉÒÔÌṩºóÆÚÒ©ÎïÓÅ»¯ÖÐÁ¬ÏµÄ£×ÓµÄÅжϱê×¼¡£
×ðÁú¿­Ê± - ÈËÉú¾ÍÊDz«!

4. °Ðµã·ÖÀà~¡°Ò©Îï¡¢ºòѡҩÎDZÔÚÒ©Îï°Ðµã¡± & ¡°ÌØÒì¡¢Ö÷µ¼¡¢ÓÅÊÆÒ©Îï°Ðµã¡±

ͨ¹ýÒ©Îï°ÐµãµÄÌØµã £¬Ðí¶àÈ˽«Ò©Îï°Ðµã·Ö³ÉÈýÀà £¬¼´¡°Ò©Îï°Ðµã¡¢ºòѡҩÎï°Ðµã¡¢Ç±ÔÚÒ©Îï°Ðµã¡±¡£ËùνҩÎï°Ðµã £¬Í¨³£ÊÇÖ¸ÄÇЩÒѾ­È·ÈÏÁ˵ÄÌØ¶¨Ò©ÎïµÄ×÷Óðе㣻ËäÈ» £¬ÈôÊÇÏìÓ¦Ò©ÎﻹûÓÐÑз¢Àֳɡ¢ÉÏÊÐ £¬Ò²²»¿É˵¾Í²»ÊÇÒ©Îï°Ðµã £¬ÕâЩÒѾ߱¸ÁËÒ©Îï°Ðµã»ù±¾ÌØÕ÷µÄÉúÎï´ó·Ö×Ó»ò·Ö×ӽṹ £¬ÉÐÐèÒ»Ö±µÄÑо¿¡¢ÆÀ¼Û £¬¹Ê³ÆÖ®ÎªºòѡҩÎï°Ðµã£»¶øÇ±ÔÚÒ©Îï°Ðµã £¬ÊÇÖ¸ÄÇЩ½ö·¢Ã÷Á˲¿·ÖÒ©Îï°ÐµãµÄÌØÕ÷ £¬µ«Éв»¾ß±¸Ò©Îï°ÐµãµÄ´ó¶¼Ìõ¼þ £¬ºÃ±È˵ÓÐЩ¾ßÓÐÖ÷Òª¹¦Ð§µÄÂѰ×ÖÊ £¬¾ß±¸²¿·ÖÒ©Îï°ÐµãµÄÌØÕ÷ £¬¿ÉÒÔ×÷Ϊһ¸öDZÔÚµÄÒ©Îï°Ðµã¡£ÉÐÓÐһЩÂѰ×ÖÊ £¬ËäÈ»·¢Ã÷ÁËһЩ¹¦Ð§ £¬µ«ÉÐûÓÐÊìϤµ½Ò©Îï°ÐµãÏà¹ØµÄ¸ü¶àµÄÌØÕ÷ £¬ÕâЩÎïÖʱ»³ÆÎªÒ©Îï°Ðµã¾ÍÌ«ÔçµãÁË £¬³äÆäÁ¿¾ÍÊÇÒ»¸ö¹¦Ð§ÂѰס£
¶øÆ¾Ö¤×÷ÓÃÓڰеãÉϵÄÒ©ÎïµÄ×÷ÓÃÌØµã £¬ÓÖ¿ÉÒÔ½«Ò©Îï°Ðµã·ÖΪ¡°ÌØÒìÒ©Îï°Ðµã¡¢Ö÷µ¼Ò©Îï°Ðµã¡¢ÓÅÊÆÒ©Îï°Ðµã¡±¡£ËùÎ½ÌØÒìÒ©Îï°Ðµã £¬¼´ÊÇÖ¸×÷ÓÃÓÚÕâÀà°ÐµãÉϵÄÒ©Îï¿ÉÒÔʩչºÜºÃµÄÒ©Àí×÷Óà £¬µÖ´ïÀíÏëµÄ·ÀÖμ²²¡µÄЧ¹û(ÆäÖаüÀ¨Ñ¡ÔñÐÔ¡¢°ÐÏòÄÚÈÝ)£»¶øÖ÷µ¼Ò©Îï°Ðµã £¬¾ÍÊǸðеãµÄÐÄÀí¡¢²¡Àí¡¢Ò©Àíѧ¹¦Ð§ÔÚ»úÌåµ÷ÀíÖÐÕ¼ÓÐÖ÷µ¼Ö°Î»£»ÉÐÓÐÒ»Àà¿ÉÒÔ³ÆÎªÓÅÊÆÒ©Îï°Ðµã £¬ÊÇÖ¸ÔÚÐÄÀí²¡ÀíÌõ¼þ϶ԻúÌåµÄµ÷Àí¾ßÓÐÓÅÊÆÖ°Î» £¬×÷ÓøðеãµÄÒ©ÎïÔÚʩչҩÀí×÷ÓõÄͬʱ £¬¿ÉÄÜÊܵ½»úÌåÕûÌåÒòËØµÄÓ°Ïì £¬¶øÌåÏÖ³öÀ´µÄ×÷ÓÃÒà¿ÉÄܱ»×ÌÈÅ £¬ÕâÀàÒ©Îï°Ðµã¿ÉÒÔ³ÆÎªÓÅÊÆÒ©Îï°Ðµã¡£

5. µ±ÏµİеãÑо¿±£´æÄÄЩÎÊÌâ


°Ðµãɸѡ²»ÑÏ
Ê×ÏÈ £¬ºòÑ¡»¯ºÏÎïÄܹ»Óë´ý¿ª·¢µÄÉúÎï´ó·Ö×ÓÁ¬Ïµ £¬²¢²»´ú±í¸ÃÉúÎï´ó·Ö×Ó¼´ÎªÒ©Îï°Ðµã¡£Ðí¶àÉúÎïÖÆÒ©¹«Ë¾ºÍÑз¢»ú¹¹ÔÚδȡµÃ¿ÆÑ§µÄͳ¼ÆÑо¿Êý¾ÝµÄÇéÐÎÏ £¬½öƾ֤ÉÙÊý¼¸¸ö¼òªµÄʵÑéЧ¹û¾ÍÒÔΪ¸Ã°Ðµã¾ßÓкܺõĿª·¢Ô¶¾° £¬´Ó¶ø´ó¹æÄ£µØ¿ªÕ¹Á¢ÒìÒ©ÎïµÄÑз¢ÊÂÇé¡£

Ñз¢±ÜÄѾÍÒ×
Ïà¶ÔÈÝÒ׿ª·¢µÄ°Ðµã £¬ÍùÍù»á»ñµÃÒ»ÎÑ·äµÄÔú¶ÑÑо¿ £¬ºÜÈÝÒ×Ñо¿¹ýÍ· £¬¶øÊ£ÏµÄһЩ¿ª¾ÙʶȽϴóµÄÉúÎï´ó·Ö×Ó £¬ÔòµÃ²»µ½ÓÅÊÆÑз¢ÊµÁ¦µÄ½øÈë £¬ÈçÂþÑÜÓÚ¶à×éÖ¯»òÓë¶à¸öµ÷Àíͨ·Óйصİеã £¬Ê¹µÃÑз¢×ÊÔ´±£´æÆÌÕÅ¡£

ÔçÆÚ¿ª·¢Ï꾡
×éºÏ»¯Ñ§¡¢¸ßͨÁ¿É¸Ñ¡±»¼ÄÓèÁËÌ«´óµÄÏ£Íû £¬Ðí¶àÖÆÒ©¹«Ë¾ÒÔΪÔÚ¾ÙÐÐÈËÌåÊÔÑé֮ǰ³ä·ÖµØÊ¹ÓÃÕâЩÏȽøµÄÊÖÒÕÀ´ÅªÇåÒ©ÎïÓë°ÐµãµÄ×÷ÓûúÖÆºÍ¿ÉÄܱ¬·¢µÄ¶¾Àíѧ¡¢Ò©¶¯Ñ§ÎÊÌâ £¬´Ó¶øÊµÏÖÒ©ÎïÓÅÑ¡µÄ×î´ó»¯ £¬ÕâÑùÒ²¾ÍÎÞÐεØÔöÌí°Ðµã¿ª·¢µÄʱ¼ä²¢½µµÍÁËÐÂÒ©ÉÏÊеÄËÙÂÊ¡£

±»ºòÑ¡»¯ºÏÎï¡°¿Ó¡±
´ý¿ª·¢µÄÉúÎï´ó·Ö×ÓÊÇ·ñÄܳÉΪҩÎï°Ðµã £¬ÊÇÐèÒªºòÑ¡»¯ºÏÎïÀ´Ö¤ÊµµÄ £¬¶øÓÐЩ»¯ºÏÎïÌìÉú¾Í±£´æÒ»Ð©¡°²Ð¼²¡± £¬ÈçÌåÄÚ´úл½Ï¿ì¡¢º¬»ùÒò¶¾½á¹¹µÈ £¬µ¼ÖÂDZÔÚµÄÒ©Îï°ÐµãҲͬ²½µÄ±»¿ÓµôÁË¡£

6. ÏÖÔÚÄÄЩÊý¾Ý¿â¿ÉÖ§³ÖÒ©Îï°ÐµãÑо¿£¿

´óÊý¾ÝÇéÐÎ֮Ϡ£¬Ò©Îï°ÐµãÑо¿ÒàÔÚÆäÖÐ £¬Êý¾Ý×ÊÔ´µÄÍÚ¾òºÍʹÓà £¬ÒѳÉΪ·¢Ã÷Ò©Îï°ÐµãµÄÖ÷Ҫ;¾¶¡£Ëæ×ÅÉúÃü¿ÆÑ§ºÍÉúÎïÐÅϢѧµÄÉú³¤ £¬Ô½À´Ô½¶àµÄ°Ðµã½á¹¹»ñµÃÆÊÎö £¬Ê¹Ò©Îï°ÐµãÊý¾Ý¿âµÄ¹¹½¨¾ßÓÐÐëÒªÐÔ¼°¿ÉÄÜÐÔ¡£¹¦Ð§»ùÒò×éѧ¡¢ÂѰ××éѧ¡¢ÏµÍ³ÉúÎïѧ¡¢¶àÏòÒ©Àíѧ¡¢ÍøÂçÒ©ÀíѧµÈÀíÂÛµÄÌá³ö £¬ÒÔ¼°ÅÌËã»ú¸¨ÖúÒ©ÎïÉè¼Æ £¬ÅÌËã»úÐéÄâɸѡµÈÅÌËã»úÊÖÒÕµÄÓ¦Óà £¬¶ÔÒ©Îï°ÐµãÊý¾Ý¿âÌá³öÁ˸ü¸ßµÄÒªÇó £¬Íƶ¯Ò©Îï°ÐµãÊý¾Ý¿â½øÒ»²½Éú³¤¡£Ò©Îï°ÐµãÊý¾Ý¿âÍøÂçºÍÕûÀíµÄÒ©Îï°ÐµãÐÅÏ¢²»¾¡Ïàͬ £¬µ«Ö÷ÒªÓÐ2Àà £¬Ò»ÊÇÕë¶ÔÒÑ֤ʵµÄÒ©Îï°Ðµã¾ÙÐÐÕûÀí¼°ÖÎÀí £¬ºÃ±È Drug Target Database¡£¶þÊdzýÁË֤ʵµÄÒ©Îï°ÐµãÍâ £¬»¹°üÀ¨Ç±ÔÚµÄÒ©Îï°ÐµãµÄÊý¾Ý¿â £¬ºÃ±ÈTTD¡£
×ðÁú¿­Ê± - ÈËÉú¾ÍÊDz«!

7. СС¸ÐÎò

¡°¹«¹²´´Òµ¡¢ÍòÖÚÁ¢Ò족 £¬ÖÆÒ©ÐÐÒµËäΪ¹Å°å £¬µ«Á¢Òì³ÌÐòÒ಻¿É»òȱ¡£ÔÚ¹ú¼ÒÃãÀø¡¢Ö§³Ö´´Á¢ÎÒÃÇ×Ô¼ºµÄ¡°ÐÂÒ©¡±Ö®Ê± £¬¸÷´ó¿ÆÑÐÔºËù¡¢¸ßУ¡¢Ò©ÆóÒà¸Ä±äÑз¢Æ«Ïò £¬ÔÚÐÂÒ©µÄ´´Ôì·½Ãæ¼Ó´óͶÈë £¬²ã²ã¼Ó×¢¡£¹ØÓÚ´ÓÊÂÐÂÒ©Ñз¢µÄ¿ÆÑÐÖ°Ô±À´Ëµ £¬Ò²Ðí×îÔçµÄ¡°ÐÂÒ©¡±¿´·¨ £¬Àë²»¿ªÈý¸ö×Ö¡°»¯ºÏÎ £¬¶ø³ÌÐò×ÔÈ»¾ÍÊDzéÎÄÏס¢Ïàʶ°Ðµã¡¢Éè¼ÆÄ¸ºË¡¢ÆÌÌì¸ÇµØµÄ»¯ºÏÎïÊýÄ¿¡¢·¢Ã÷Ïȵ¼¡¢½á¹¹ÓÅ»¯......µÈµÈµÈµÈ £¬¸ü¶àµÄ¾«Éñ¿ÉÄÜ»á·ÅÔÚ×ö»¯ºÏÎï¡¢ÆÚÅÎÒ©ÀíÊý¾ÝµÄ¡°±¨Ïþ¡±µÈ·½Ãæ¡£ÏÖÔÚÌì £¬×ðÁú¿­Ê±Ñз¢³ÌÐò¿ÉÄܸı䲻´ó £¬µ«ÒªÇ¿µ÷µÄÊÇ £¬¶Ô°ÐµãµÄ¡°ÏÓÒÉ¡±¿Éνʱ¿Ì²»¸ÒµôÒÔÇáÐÄ £¬ÒªÖªµÀ £¬ÊÖÒÕÉϵĹýʧ¿ÉÒÔÖð½¥Ìî²¹ £¬µ«Æ«ÏòÉϵĹýʧ £¬¾ø¶ÔÊÇÖÂÃüµÄ¡£¹Ê¶ø £¬Ò©ÎﻯѧµÄÊÂÇéÒ²¾Í¸ü¶àµÄҪȥѧϰҩÀíѧ¡¢·Ö×ÓÉúÎïѧµÈÏà¹ØÑ§¿ÆµÄÄÚÈÝ £¬Ö»Óжàѧ¿ÆµÄ¾ÙÐÐÔÓôÛ £¬²¢ÐγÉÒ»¶¨µÄÌ«¼« £¬Ò²Ðí²Å»ª¸üºÃµÄÒâ»á¡°°Ðµã¡±¡¢Òâ»á¡°ÐÂÒ©¡±£¡

²Î¿¼ÎÄÏ×£º
1. ZC Li £¬WQ Zhong £¬ZQ Liu £¬etal. Large-scale identification of potential drugtargets based on the topological features of human protein-protein interaction network [J]. Analytica Chimica Acta £¬ 2015 £¬ 871: 18-27.
2. P Kumari £¬A Nath £¬R Chaube. Identification of human drug targets using machine-learning algorithms [J].Computers in Biology &Medicine £¬2015 £¬56 (56C) :175-181.
3. CM Pichler £¬J Krysiak £¬R Breinbauer. Target identification of covalently binding drugs by activity-based protein profiling [J]. Bioorganic & Medicinal Chemistry £¬2016 £¬24 (15) :3291.
4. R Breinbauer. Target identification of small molecule drugs and chemical probes [J]. Bioorganic & Medicinal Chemistry £¬2016 £¬24 (15): 3231.
5. T Katsila £¬GA Spyroulias £¬GP Patrinos £¬et al. Computational approaches in target identification and drug discovery [J]. Computational& Structural Biotechnology Journal £¬2016 £¬14: 177-184.
6. WMMVD Broeck. Chapter 3-Drug Targets £¬Target Identification £¬Validation £¬and Screening [J]. Practice of Medicinal Chemistry £¬2015: 45-70.
7. ¶Å¹Ú»ª.Ò©Îï°ÐµãµÄ·¢Ã÷ºÍÈ·Ö¤Ñо¿[C]. ÖйúÒ©Àíѧ»áҩѧÉú³¤Ç°ÑØÂÛ̳ £¬ 2008:24-26.
8. ÕÅÒô £¬ÍõËÉ¿¡ £¬µóÌìϲ.Ò©Îï°ÐµãµÄÉú³¤Ô¶¾°¼°ÐèÒª½â¾öµÄÒªº¦ÎÊÌâ [J]. ÖйúÐÂÒ©ÔÓÖ¾ £¬2009 (19): 1834-1837.
9. ´Þ´óÃ÷.Ò©Îï°ÐµãɸѡµÄÑо¿ [J]. ÖйúÎÀÉú¹¤Òµ £¬2013 (14): 187-187.
10. ÅÓÏþ´Ô £¬Áõ°¬ÁÖ £¬¶Å¹Ú»ª.Ò©Îï°ÐµãÊý¾Ý¿âµÄÓ¦ÓÃÏ£Íû[J].ÖйúҩѧÔÓÖ¾ £¬2014 £¬49(22): 1969-1972.
Ïà¹ØÐÂÎÅ
¡Á
ËÑË÷ÑéÖ¤
µã»÷Çл»
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿